COMPANY

iVeena Delivery Systems, Inc.

HQ: Salt Lake City, UT source · iveenamed.com ↗ · Mountain

Also known as iVeena Delivery Systems · 14 sources

Keywords: keratoconus myopia macular degeneration Safety Study Progressive Myopia Corneal Ectasia IVMED-85 IVMED 85 IVMED-80

Location: Salt Lake City, UT · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)9NIH grants

Funding and NIH signals

NIH award NIH awarded $1.11M (SBIR Phase II 5R44EY034770-03, continuation, notice Sep 11, 2026). NIH RePORTER 5R44EY034770-03 (Sep 11, 2026)
Evidence (1 event)
- Sep 11, 2026 · NIH RePORTER 5R44EY034770-03
  Organization: IVEENA DELIVERY SYSTEMS, INC.; City/State: SALT LAKE CITY, UT; Project number: 5R44EY034770-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 1111998; Administering IC: National Eye Institute; Project title: Topical Eyedrops Increasing Lysyl Oxidase and Dopamine Activity to Control Myopia; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Series B · $3M · announced Feb 5, 2025 Company release ↗
Source quote
- Feb 5, 2025 · Company release ↗
  “(“iVeena”) , a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million.”

Raises announced in these releases: $3M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 11, 2026 Grant Government grant — SBIR: $1.11M (annual award, as published), announced Sep 11, 2026. Agency: NIH/NEI. Source: government award database. source ↗
Feb 4, 2026 Trial start Phase 1: A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults source ↗
Aug 28, 2025 Grant Government grant — SBIR: $933,817 (annual award, as published), announced Aug 28, 2025. Agency: NIH/NEI. Source: government award database. source ↗
Feb 5, 2025 Raise Series B · $3M source ↗
Feb 8, 2019 Trial start Phase 1/Phase 2: Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients source ↗
2024-02 Trial start Phase 1/Phase 2: Efficacy of IVMED-85 on Pediatric Myopia source ↗

Funding

Last 2 years.

Sep 11, 2026 Government grant — SBIR: $1.11M (annual award, as published), announced Sep 11, 2026. Agency: NIH/NEI. Source: government award database. source ↗
Aug 28, 2025 Government grant — SBIR: $933,817 (annual award, as published), announced Aug 28, 2025. Agency: NIH/NEI. Source: government award database. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07370584	A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults	Phase 1	Recruiting	Feb 4, 2026	2026-05 (estimated)
NCT05761795	Efficacy of IVMED-85 on Pediatric Myopia	Phase 1/Phase 2	Not yet recruiting	2024-02	2026-05 (estimated)
NCT05241145	Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients	Phase 1/Phase 2	Completed	Feb 8, 2019	Jul 8, 2020 (actual)

NIH awards 9

Annual award amounts. Total $4.5M.

Sep 18, 2023 NIH award 1R43EY034770-01 FY2023: $345,000 awarded for that fiscal year; activity R43 (SBIR); PI MOLOKHIA, SARAH ABDULLA; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Topical Eyedrops Incr source ↗
Aug 27, 2021 NIH award 5R44EY031224-02 FY2021: $909,474 awarded for that fiscal year; activity R44 (SBIR); PI MOLOKHIA, SARAH ABDULLA; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Topical Eyedrop Thera source ↗
Aug 21, 2020 NIH award 1R44EY031224-01A1 FY2020: $771,002 awarded for that fiscal year; activity R44 (SBIR); PI MOLOKHIA, SARAH ABDULLA; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Topical Eyedrop The source ↗
Jul 29, 2020 NIH award 5R44EY024501-03 FY2020: $1,002,479 awarded for that fiscal year; activity R44 (SBIR); PI BURR, RANDON MICHAEL; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Targeted Intraceptors source ↗
Apr 13, 2020 NIH award 3R44EY024501-02A1S1 FY2020: $458,234 awarded for that fiscal year; activity R44 (SBIR); PI BURR, RANDON MICHAEL; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Targeted Intraceptor source ↗
Sep 19, 2019 NIH award 2R44EY024501-02A1 FY2019: $544,245 awarded for that fiscal year; activity R44 (SBIR); PI BURR, RANDON MICHAEL; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Targeted Intraceptors source ↗
Sep 6, 2017 NIH award 1R43EY027636-01A1 FY2017: $224,767 awarded for that fiscal year; activity R43 (SBIR); PI MOLOKHIA, SARAH ABDULLA; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Topical Eyedrop The source ↗
Sep 15, 2015 NIH award 3R43EY024501-01A1S1 FY2015: $24,950 awarded for that fiscal year; activity R43 (SBIR); PI PATIL, RAJKUMAR; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Targeted Intraceptor Nanop source ↗
Dec 29, 2014 NIH award 1R43EY024501-01A1 FY2015: $216,736 awarded for that fiscal year; activity R43 (SBIR); PI PATIL, RAJKUMAR; recipient as written: IVEENA DELIVERY SYSTEMS, INC., SALT LAKE CITY, UT. Targeted Intraceptor Nanopa source ↗